<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Chemotherapy regimens for extensive stage small cell lung cancer: Cisplatin (60 mg/m&lt;sup&gt;2&lt;/sup&gt;) plus etoposide&lt;sup&gt;[1]&lt;/sup&gt;</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Chemotherapy regimens for extensive stage small cell lung cancer: Cisplatin (60 mg/m<sup>2</sup>) plus etoposide<sup>[1]</sup></h1>
<div class="graphic"><div class="figure"><div class="ttl">Chemotherapy regimens for extensive stage small cell lung cancer: Cisplatin (60 mg/m<sup>2</sup>) plus etoposide<sup>[1]</sup></div><div class="cntnt"><table cellspacing="0"><colgroup span="6" width="16.66%"></colgroup> <tbody> <tr class="divider_bottom"> <td colspan="6"><strong>Cycle length:</strong> Every 21 days for four cycles. </td> </tr> <tr class="divider_top"> <td class="subtitle1 divider_bottom">Drug</td> <td class="subtitle1 divider_bottom">Dose and route</td> <td class="subtitle1 divider_bottom" colspan="3">Administration</td> <td class="subtitle1 divider_bottom">Given on days</td> </tr> <tr> <td>Cisplatin</td> <td>60 mg/m<sup>2</sup> IV</td> <td colspan="3">Dilute in 250 mL normal saline (NS) and administer over 60 minutes. Do not administer with aluminum needles or sets.</td> <td>Day 1</td> </tr> <tr class="divider_bottom"> <td>Etoposide</td> <td>120 mg/m<sup>2</sup> IV daily</td> <td colspan="3">Dilute in 500 mL NS* or 5% dextrose in water (D5W) to final concentration &lt;0.4 mg/mL. Infuse over 30 to 60 minutes; if infused more rapidly, severe hypotension may occur.</td> <td>Days 1, 2, and 3</td> </tr> <tr class="divider_top"> <td class="subtitle1_left" colspan="6">Pretreatment considerations:</td> </tr> <tr> <td class="indent1"><strong>Hydration</strong></td> <td colspan="5"> <ul> <li>IV fluid to establish a urine flow of at least 100 mL/hour for at least two hours prior to and two hours after cisplatin administration. </li> <li>Refer to UpToDate topics on cisplatin nephrotoxicity. </li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Emesis risk</strong></td> <td colspan="5"> <ul> <li>HIGH. </li> <li>Refer to UpToDate topics on prevention of chemotherapy-induced nausea and vomiting in adults. </li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Prophylaxis for infusion reactions</strong></td> <td colspan="5"> <ul> <li>Routine prophylaxis not indicated. </li> <li>Refer to UpToDate topics on infusion reactions to systemic chemotherapy. </li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Vesicant/irritant properties</strong></td> <td colspan="5"> <ul> <li>Cisplatin is an irritant but can cause significant tissue damage; avoid extravasation. </li> <li>Refer to UpToDate topics on extravasation injury from chemotherapy and other non-antineoplastic vesicants. </li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Infection prophylaxis</strong></td> <td colspan="5"> <ul> <li>Primary prophylaxis with hematopoietic growth factors is not recommended. </li> <li>Refer to UpToDate topics on use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation. </li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="indent1"><strong>Dose adjustment for baseline liver or kidney dysfunction</strong></td> <td colspan="5"> <ul> <li>The optimal approach to cisplatin therapy in patients with preexisting kidney impairment is unknown. Such patients were excluded from the original trial.<sup>[1]</sup> A lower starting dose of etoposide may be needed for patients with kidney or liver impairment.<sup>[2]</sup> </li> <li>Refer to UpToDate topics on chemotherapy hepatotoxicity and dose modification in patients with liver disease, conventional cytotoxic agents; chemotherapy hepatotoxicity and dose modification in patients with liver disease, molecularly targeted agents; and chemotherapy nephrotoxicity and dose modification in patients with kidney impairment, conventional cytotoxic agents.</li> </ul> </td> </tr> <tr class="divider_top"> <td class="subtitle1_left" colspan="6">Monitoring parameters:</td> </tr> <tr> <td colspan="6"> <ul class="decimal_heading"> <li>CBC with differential and platelet count weekly during treatment. </li> </ul> </td> </tr> <tr> <td colspan="6"> <ul class="decimal_heading"> <li>Basic metabolic panel (creatinine and electrolytes) and liver function tests prior to each cycle. </li> </ul> </td> </tr> <tr class="divider_bottom"> <td colspan="6"> <ul class="decimal_heading"> <li>Monitor for hearing loss prior to each dose of cisplatin; audiometry as clinically indicated. </li> </ul> </td> </tr> <tr class="divider_top"> <td class="subtitle1_left" colspan="6">Suggested dose modifications for toxicity:</td> </tr> <tr> <td class="indent1 divider_bottom" rowspan="5"><strong>Myelotoxicity</strong></td> <td colspan="5"> <ul> <li>Day 1 ANC should be &gt;1500 cells/microL and platelets should be &gt;75,000/microL for treatment during each cycle. Etoposide dose reductions should be based on the following table, taking into account the nadir ANC and platelet count along with day 1 ANC and platelet count for each cycle.<sup>[1]</sup> </li> </ul> </td> </tr> <tr> <td class="subtitle3">Etoposide dose</td> <td class="subtitle3">Nadir ANC (cells/mm)</td> <td class="subtitle3">Nadir platelet count per microL</td> <td class="subtitle3">Day 1 ANC</td> <td class="subtitle3">Day 1 platelet</td> </tr> <tr> <td>25% reduction</td> <td>750 to 999</td> <td>50,000 to 99,999</td> <td>&gt;2000</td> <td>&gt;100,000</td> </tr> <tr> <td>50% reduction</td> <td>&lt;750</td> <td>&lt;50,000</td> <td>&gt;2000</td> <td> </td> </tr> <tr class="divider_bottom"> <td>Hold</td> <td>&lt;750</td> <td>&lt;50,000</td> <td>1500 to 2000</td> <td>75,000 to 100,000</td> </tr> <tr class="divider_bottom"> <td class="indent1"><strong>Neurotoxicity</strong></td> <td colspan="5"> <ul> <li>Neuropathy usually is seen with cumulative doses of cisplatin &gt;400 mg/m<sup>2</sup>, although there is marked interindividual variation. </li> <li>Refer to UpToDate topics on overview of neurologic complications of platinum-based chemotherapy. </li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="indent1"><strong>Nephrotoxicity</strong></td> <td colspan="5"> <ul> <li>Hold cisplatin until serum creatinine &lt;1.5 mg/dL and/or blood urea nitrogen &lt;25 mg/dL. For grade ≥2 nephrotoxicity during treatment (creatinine &gt;1.5 times normal value despite adequate hydration), creatinine clearance should be determined prior to next cycle, and cisplatin dose reduced if &lt;60 mL/min. </li> <li>Refer to UpToDate topics on cisplatin nephrotoxicity. </li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="indent1"><strong>Other severe non-hematologic toxicity</strong></td> <td colspan="5"> <ul> <li>Etoposide and cisplatin should be withheld or doses decreased depending on clinical judgement. </li> </ul> </td> </tr> <tr class="divider_top"> <td class="highlight_gray_text" colspan="6" style="font-size: 1.2em;"><strong>If there is a change in body weight of at least 10%, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class="graphic_lgnd"><strong>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy, who should use independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</strong></div><div class="graphic_footnotes"><p> ANC: absolute neutrophil count; CBC: complete blood count; IV: intravenous.</p><p>
* Diluent solutions should not be modified without consulting a detailed reference due to potential incompatibility(ies).</p></div><div class="graphic_reference">References:
<ol>
<li>Schiller JH, Adak S, Cella D, et al. Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593--a phase III trial of the Eastern Cooperative Oncology Group J Clin Oncol 2001; 19:2114.</li>
<li>Etoposide injection. United States Prescribing Information. US National Library of Medicine. (Available online at <a href="https://www.dailymed.nlm.nih.gov/dailymed/" target="_blank">dailymed.nlm.nih.gov</a>, accessed December 8, 2011).</li>
</ol></div><div id="graphicVersion">Graphic 58176 Version 26.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
